Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CPN1 | P15169 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.37 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12413711 | 0.90 | KCNH2 (0.43) | RAB9ACYP3A4HPGDCYP2C19KCNH2 | |
| SCHEMBL1776646 | 0.90 | KCNH2 (0.43) | RAB9ACYP3A4HPGDCYP2C19KCNH2 | |
| SCHEMBL17066213 | 0.83 | SMN1; SMN2 (0.40) | RAB9ACYP3A4HPGDCYP2C19EPHX1 | |
| SCHEMBL16509289 | 0.81 | MAPK1 (0.47) | MAPK1OPRK1CPN1CPB2NLRP3 | |
| SCHEMBL12507029 | 0.81 | MAPK1 (0.47) | MAPK1OPRK1CPN1CPB2NLRP3 | |
| SCHEMBL11890370 | 0.81 | RAB9A (0.54) | RAB9ACYP3A4HPGDCYP2C19EPHX1 | |
| SCHEMBL11890375 | 0.81 | RAB9A (0.58) | RAB9ACYP3A4HPGDCYP2C19EPHX1 | |
| SCHEMBL11890392 | 0.80 | EPHX1 (0.53) | RAB9ACYP3A4HPGDCYP2C19CHRM5 | |
| SCHEMBL8241745 | 0.79 | EPHX1 (0.58) | RAB9ACYP3A4HPGDCYP2C19EPHX1 | |
| SCHEMBL13460003 | 0.79 | GNAI3 (0.49) | MAPK1OPRK1HPGDNLRP3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293729-B2 | Compounds, pharmaceutical composition and methods relating thereto | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166116-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO | MC2R, REN, CYP11B2 | MAPK1 4047/4885OPRK1 1016/4885RAB9A 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.